Motixafortide
Also known as: Aphexda, BL-8040, BSN324, Motixafortide, POL6326
Source Motixafortide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Motixafortide is a cyclic peptide that antagonises the chemokine receptor CXCR4. It is approved in the United States, in combination with filgrastim, to mobilise peripheral blood haematopoietic stem and progenitor cells for autologous transplantation in patients with multiple myeloma. Ongoing studies are evaluating its use in acute myeloid leukaemia, pancreatic cancer and gene‑therapy approaches for sickle‑cell disease.
Mechanism of Action
Motixafortide binds selectively to CXCR4, blocking the interaction with its ligand CXCL12 (SDF‑1). This disrupts the CXCL12‑CXCR4 retention signal that normally holds haematopoietic stem cells in the bone‑marrow niche, allowing them to enter the circulation. In malignancies, CXCR4 inhibition can interfere with tumour cell trafficking, survival signalling and chemoresistance pathways.
What the Research Shows
A phase‑3, double‑blind GENESIS trial in multiple myeloma showed that motixafortide plus G‑CSF achieved the primary endpoint—collection of ≥6 × 10⁶ CD34⁺ cells kg⁻¹ within two apheresis procedures—in 92.5% of patients versus 26.2% with placebo + G‑CSF, with an odds ratio of 53.3 (P < 0.0001). The same regimen also met a secondary endpoint (single‑procedure collection) in 88.8% versus 9.5% (OR 118.0). Safety was favourable, with only transient grade 1/2 injection‑site reactions. Review articles describe motixafortide among emerging CXCR4 antagonists for acute myeloid leukaemia and other CXCR4‑expressing tumours. Early‑phase combination trials in pancreatic ductal adenocarcinoma reported limited objective responses and higher rates of grade 3‑5 adverse events, indicating modest efficacy outside stem‑cell mobilisation. The drug holds orphan‑drug designations for pancreatic cancer and AML and is being explored for sickle‑cell gene‑therapy mobilisation.
Reported Benefits
In the GENESIS trial motixafortide markedly increased successful stem‑cell collection rates (92.5% vs 26.2%) and enabled single‑procedure harvest in most patients, potentially reducing apheresis burden. The peptide preferentially mobilises primitive HSPCs, which may improve transplant outcomes. Across studies it was generally well tolerated, with only mild injection‑site discomfort reported. Early data suggest possible activity against CXCR4‑driven malignancies, supporting further investigation.
Limitations of the Evidence
Robust efficacy data are currently limited to stem‑cell mobilisation in multiple myeloma; benefits in solid tumours or other haematologic cancers remain unproven. The pancreatic cancer arm of the MORPHEUS‑PDAC study showed low response rates and a high incidence of serious adverse events, highlighting uncertain therapeutic value outside mobilisation. Long‑term safety and survival outcomes have not been fully characterised, and optimal dosing regimens are still under study.
Safety Considerations
The most common adverse events in the phase‑3 mobilisation trial were transient grade 1/2 injection‑site reactions (pain 50%, erythema 27.5%, pruritus 21.3%). No serious systemic toxicities were reported in that study. In combination trials for pancreatic cancer, grade 3‑5 adverse events occurred in over half of patients, reflecting the added agents rather than motixafortide alone. Overall, the peptide appears to have a favourable short‑term safety profile when used for stem‑cell mobilisation.
How It Is Administered
Motixafortide is administered by subcutaneous injection, typically in conjunction with daily filgrastim (G‑CSF) during the stem‑cell mobilisation phase preceding autologous transplantation. The formulation is a sterile peptide solution; dosing schedules are defined by clinical trial protocols and the approved indication, but generally involve a single or short‑course injection series to achieve peripheral CD34⁺ mobilisation.
Routes of Administration
Goals & Uses
- Enhancement of anti‑tumor immunityOncologyModerate
- Hematopoietic stem cell mobilizationHematologyHigh
- Pancreatic cancer treatmentOncologyLow
- Reduction of apheresis sessionsProcedural EfficiencyHigh
- Acute Myeloid Leukemia (AML) TreatmentHematology/OncologyLow
Contraindications
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Known hypersensitivity to motixafortide or excipientsAllergyHigh
- Active systemic infectionInfectiousModerate
- Hypersensitivity to motixafortide or any excipientAllergyHigh
Adverse Effects
- Injection site reactionsLocalCommon
- Hypersensitivity/anaphylaxisImmunologicalUncommon
- HypotensionCardiovascularRareLow blood pressure
- Nausea/vomitingGastrointestinalCommon
- FlushingVascularCommonWarmth and redness of the skin
- Orthostatic hypotensionCardiovascularUncommon
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- Transient leukocytosisHematologicalUncommon
- Injection site erythemaLocalCommonRedness at the injection site
- DizzinessNeurologicCommonFeeling faint, lightheaded, or unsteady
Drug Interactions
- Granulocyte‑colony stimulating factor (G‑CSF)Moderate
- Filgrastim (G-CSF)Low
- Other CXCR4 antagonistsHigh
- PlerixaforModerate
Population Constraints
- PregnancyReproductive SafetyRelative
- Severe renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- LactationReproductiveRelative
- Elderly (>75 years)GeriatricRelative
Regulatory Status
- European UnionInvestigationalUnder EMA review for stem‑cell mobilization.
- United StatesInvestigationalPhase 3 trials ongoing; not FDA‑approved.
- United KingdomInvestigationalClinical trials authorized; not MHRA‑approved.
FDA approved August 2023 under the brand name Aphexda in combination with filgrastim for HSC mobilization in multiple myeloma patients. Orphan Drug Designation granted. Not yet approved in EU or UK as of 2024.
Evidence & Sources
- Journal ArticleModerateHoy SM2023-01-01T00:00:00.000000Z
- Journal ArticleModerateMiao M, De Clercq E, Li G2020-01-01T00:00:00.000000Z
- Journal ArticleModerateKorbecki J, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleModerateCrees ZD, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleModerateMartin M, et al.2021-01-01T00:00:00.000000Z
- Journal ArticleModerateManji GA, et al.2026-01-01T00:00:00.000000Z
Frequently Asked Questions
What condition is motixafortide officially approved to treat?
It is FDA‑approved for use with filgrastim to mobilise peripheral‑blood haematopoietic stem cells in adults with multiple myeloma who are undergoing autologous stem‑cell transplantation.
How does motixafortide differ from the older CXCR4 antagonist plerixafor?
Motixafortide is a cyclic peptide with a longer in‑vivo half‑life, allowing extended CXCR4 blockade, whereas plerixafor is a small‑molecule with a shorter duration of action. Clinical data suggest motixafortide achieves higher stem‑cell yields in fewer apheresis sessions.
Can motixafortide be used for cancers other than multiple myeloma?
Early‑phase studies are exploring its use in acute myeloid leukaemia, pancreatic cancer and sickle‑cell gene‑therapy mobilisation, but efficacy outside stem‑cell mobilisation has not yet been demonstrated and it remains investigational for those indications.
What are the most common side effects patients experience?
Patients most frequently report mild injection‑site reactions such as pain, redness and itching. In the mobilisation trial these were grade 1 or 2 and transient. More severe adverse events have been observed only in combination regimens for solid tumours.
How is motixafortide given in practice?
It is delivered as a subcutaneous injection, usually alongside daily filgrastim injections during the mobilisation window before apheresis. The exact timing and number of doses follow the protocol approved for multiple myeloma stem‑cell collection.
What is Motixafortide?
Motixafortide is a cyclic peptide that antagonises the chemokine receptor CXCR4. It is approved in the United States, in combination with filgrastim, to mobilise peripheral blood haematopoietic stem and progenitor cells for autologous transplantation in patients with multiple myeloma. Ongoing studies are evaluating its use in acute myeloid leukaemia, pancreatic cancer and gene‑therapy approaches for sickle‑cell disease.
What is Motixafortide used for?
Motixafortide is educationally associated with: Enhancement of anti‑tumor immunity, Hematopoietic stem cell mobilization, Pancreatic cancer treatment, Reduction of apheresis sessions, Acute Myeloid Leukemia (AML) Treatment. Educational only — not medical advice.
How is Motixafortide administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Motixafortide?
Reported adverse effects include: Injection site reactions, Hypersensitivity/anaphylaxis, Hypotension, Nausea/vomiting, Flushing, Orthostatic hypotension, Nausea, Transient leukocytosis, Injection site erythema, Dizziness. This list is not exhaustive — consult a qualified clinician.
Who should avoid Motixafortide?
Recorded contraindications: Pregnancy, Known hypersensitivity to motixafortide or excipients, Active systemic infection, Hypersensitivity to motixafortide or any excipient. Consult a qualified clinician before use.